BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Part of paid clinical trials in Nashville, Tennessee.
- Sponsor
- Vanderbilt University Medical Center
- Study ID
- NCT05051631
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 25 Years - 49 Years
- Healthy Volunteers
- Accepted
Interventions
- Intervention plus 12 months maintenance — OTHERThe intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
- Intervention plus 10 months maintenance — OTHERThe intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
- Intervention plus 8 months maintenance — OTHERThe intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
- Intervention plus 6 months maintenance — OTHERThe intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
- Intervention plus 4 months maintenance — OTHERThe intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
Study Details
The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of select customized strategies to increase uptake of breast cancer risk assessment. The investigators will achieve these aims through a conducting a stepped-wedge trial conducted in 10 healthcare clinics in the state of Tennessee. The primary outcome is the proportion of women age 25-49 having risk assessment. Secondary outcomes include the numbers of 1) women identified as high-risk; 2) pursuing risk-adherent screening; and 3) diagnosed with breast cancer.
Key Dates
- Start date
- Mar 9, 2022
- Status verified
- Aug 2025
- Primary completion
- Aug 30, 2024
- Completion
- Aug 30, 2024
Study Design
- Enrollment
- 1,071 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Experimental: Intervention plus 12 months maintenanceClinics in this group will be in the control phase for 2 months, receive the 4 month intervention, and be in the maintenance phase for 12 months.
- Experimental: Intervention plus 10 months maintenanceClinics in this group will be in the control phase for 4 months, receive the 4 month intervention, and be in the maintenance phase for 10 months.
- Experimental: Intervention plus 8 months maintenanceClinics in this group will be in the control phase for 6 months, receive the 4 month intervention, and be in the maintenance phase for 8 months.
- Experimental: Intervention plus 6 months maintenanceClinics in this group will be in the control phase for 8 months, receive the 4 month intervention, and be in the maintenance phase for 6 months.
- Experimental: Intervention plus 4 months maintenanceClinics in this group will be in the control phase for 10 months, receive the 4 month intervention, and be in the maintenance phase for 4 months.
Primary Outcome Measure
Number of Eligible Women Who Received Breast Cancer Risk Assessment [ Time Frame: Baseline (2-months prior to intervention) to 9 months post-intervention ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | - |
Find similar trials in Nashville, TN
Related Studies
- Collecting and Storing Tissue Samples From Women With or Without Breast CancerRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama